Office:	1218 Scaife Hall
	3550 Terrace Street
	Pittsburgh, PA 15261
Phone:	412-648-9636
Fax:	412-648-2117
E-mail:	gladwinmt@upmc.edu

Education
	BS and MD, University of Miami Honors Program, 1991

Training
	Internship, Residency, Oregon Health Sciences University, 1994
	Chief Resident, Oregon Health Sciences University, 1995
	Critical Care Fellow, Warren G. Magnuson Clinical Center, NIH, 1996
	Pulmonary-Critical Care Fellow, University of Washington, 1998

Since 1998, Dr. Gladwin's research activities have led to numerous scientific discoveries. These discoveries have resulted in more than 210 published peer-reviewed manuscripts. These investigations form the backbone of Dr. Gladwin’s current work in the Department of Medicine: 1) The discovery that the nitrite anion is a circulating storage pool for NO bioactivity (Gladwin, et al. PNAS 2000) that regulates hypoxic vasodilation (Cosby Nature Medicine 2003) and the cellular resilience to low oxygen and ischemia (Duranski JCI 2005). 2) The discovery of a novel physiological function for hemoglobin as an electronically and allosterically-regulated nitrite reductase (Cosby, et al. Nature Medicine 2003; Huang et al. JCI 2005). 3) The characterization of a novel mechanism of disease, hemolysis-associated endothelial dysfunction (Reiter, et al. Nature Medicine 2002; Morris et al. JAMA 2005; Minneci et al. JCI 2005; Rother et al. JAMA 2005). 4) The mechanistic, clinical, and epidemiological description of a human disease syndrome, hemolysis-associated pulmonary hypertension (Gladwin, et al. NEJM 2004).

Dr. Gladwin's clinical specialty is in the diagnosis and treatment of patients with pulmonary hypertension and sickle cell disease. He is an expert in heart and lung complications of sickle cell disease, which occur with increasing frequency as patients are aging. He also attends regularly in the Medical Intensive Care Unit at Presbyterian Hospital, focused on the care of critically ill patients and their families. Dr. Gladwin’s clinical research focuses on pulmonary hypertension and pulmonary complications of sickle cell disease. He currently serves as PI on a new multi-center clinical trial of Riociguat to treat patients with sickle cell disease and pulmonary hypertension, and has served as PI on the multi-center clinical trials Walk-PHASST (Pulmonary Hypertension and Sickle Sildenafil Therapy Trial) and DeNOVO (Delivery of NO for Vaso-Occlusive pain crisis in sickle cell disease). He has served as a principal or associate investigator on more than 50 human subjects protocols and has held 10 FDA INDs for the use of investigational therapeutic medications, including inhaled, intravenous and oral preparations of sodium nitrite, carbon monoxide, L-NMMA, acetylcholine, riociguat and sildenafil.

For my complete bibliography, Click Here.

Selected Publications: